SLC16A9

Across TCGA pan-cancer cohorts, SLC16A9 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated SLC16A9 data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher SLC16A9 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC16A9 expression acts as an unfavorable survival marker, although some lineages such as UCEC and SKCM show a favorable association.

BRCA, LUAD, and UCEC are the cancer types where SLC16A9 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.553	0.963	<.001	48	view →
LUAD	OS	Median	II,III,IV	0.004	0.751	<.001	22	view →
UCEC	DFS	Median	All	0.955	0.626	.023	20	view →
KIRC	OS	Median	All	0.122	0.629	.019	12	view →
SCLC	OS	Median	All	0.219	0.706	.011	6	view →
BLCA	OS	Median	III,IV	0.163	0.579	.012	6	view →
LIHC	OS	Median	All	0.031	0.775	<.001	6	view →
SKCM	DFS	Median	IV	1.000	0.241	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

SLC16A9–BRCA (OS)

Open the BRCA breakdown →